CA
PCVX icon

Clearstead Advisors’s Vaxcyte PCVX Stock Holding History

Clearstead Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.14K Buy
+140
New +$7.6K ﹤0.01% 2052
2026
Q1 		– Sell
-3,635
Closed -$168K – 2688
2025
Q4 		$168K Buy
3,635
+2,509
+223% +$112K ﹤0.01% 968
2025
Q3 		$40.6K Buy
1,126
+100
+10% +$3.31K ﹤0.01% 1344
2025
Q2 		$33.4K Buy
1,026
+708
+223% +$23.2K ﹤0.01% 1424
2025
Q1 		$12K Buy
318
+158
+99% +$12.6K ﹤0.01% 1564
2024
Q4 		$13.1K Sell
160
-745
-82% -$74K ﹤0.01% 1508
2024
Q3 		$103K Buy
905
+16
+2% +$1.44K ﹤0.01% 1023
2024
Q2 		$67.1K Buy
889
+114
+15% +$7.76K ﹤0.01% 1092
2024
Q1 		$50.9K Buy
775
+235
+44% +$16.3K ﹤0.01% 754
2023
Q4 		$33.9K Buy
540
+130
+32% +$6.75K ﹤0.01% 836
2023
Q3 		$20.9K Buy
+410
New +$20.2K ﹤0.01% 884

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Clearstead Advisors's PCVX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Vaxcyte (PCVX) in Q2 2026: 140 shares worth $8.14K. The stake represents ﹤0.01% of the portfolio and ranks #2052 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in PCVX as recently as Q4 2025.

Clearstead Advisors first reported a position in PCVX in Q3 2023 and has held it in 11 quarters since. The position peaked at $168K in Q4 2025. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Clearstead Advisors held 140 shares of Vaxcyte worth $8.14K as of Q2 2026.
  • Vaxcyte was a new Clearstead Advisors position in Q2 2026.
  • Vaxcyte made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2052 holding.
  • Clearstead Advisors first reported a position in Vaxcyte in Q3 2023 and has held it in 11 quarters since.
  • Clearstead Advisors's Vaxcyte position peaked at $168K in Q4 2025.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.